Investor presentation outlines growth plan and financial targets
ASP Isotopes outlined a multi-business execution plan spanning isotope enrichment, nuclear medicine, electronics materials, helium and LNG, nuclear fuels.
FY 2026 revenue forecast set above USD 14 million; Q2 2026 revenue reported at USD 5.1 million.
Cash and cash equivalents totaled USD 254.9 million as of June 30, 2026; workforce cited at more than 400 employees.
Helium milestone flagged as imminent; first production targeted before September 30, 2026; Phase 1 revenue run-rate projected near USD 27 million.
2031 EBITDA target set above USD 300 million; three enrichment plants in Pretoria described as operating across carbon-14, silicon-28, ytterbium-176.
ASPI•
